Collagenase injection

Drug Profile

Collagenase injection

Alternative Names: AA-4500; AK-160; CCH; Clostridial collagenase; Collagenase clostridium histolyticum; Cordase; EN-3835; PF-5076985; Plaquase; XIAFLEX; Xiapex

Latest Information Update: 06 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator BioSpecifics Technologies Corporation
  • Developer Actelion Pharmaceuticals; Asahi Kasei; BioSpecifics Technologies Corporation; Endo International; Swedish Orphan Biovitrum
  • Class Collagenases; Urologics
  • Mechanism of Action Collagen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dupuytren's contracture; Peyronie's disease
  • New Molecular Entity No
  • Available For Licensing Yes - Dupuytren's contracture; Peyronie's disease

Highest Development Phases

  • Marketed Dupuytren's contracture; Peyronie's disease
  • Phase II Cellulite; Frozen shoulder; Lipoma
  • Phase I Uterine leiomyoma
  • Preclinical Breast disorders
  • Research Metabolic disorders; Musculoskeletal disorders
  • Discontinued Hypertrophic scars; Keloids; Tendon injuries

Most Recent Events

  • 30 Jun 2017 NICE recommends collagenase injection as an option for treating Dupuytren's contracture in adults who are not taking part in an ongoing clinical trial
  • 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
  • 29 Mar 2017 BioSpecifics Technologies Corporation plans a clinical trial for Uterine leiomyoma in the first quarter of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top